Evangeline Lilly, 45, shares shocking photos of her facial injuries after horror fall at the beach
The Lost icon, 45, took to her Instagram page on Friday and posted a series of snaps looking bloodied and bruised.
You are not logged in so some information on this page has been withheld. To see more, please log in.
Lilly
since
auto-detected in 536 stories
3 days ago
6 days ago
Transgender influencer refuses to eat meal at Disney World because waiter accidentally called her 'sir'
found
a story from The Daily Mail 💩 › The Daily Mail
Lilly Contino shared her dismay after a waiter at the Happiest Place On Earth accidentally misgendered her, and she said she 'no longer felt safe' at the restaurant.
Eli Lilly to buy privately held SiteOne in deal worth up to $1 billion
Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday.
13 days ago
Lilly Sabri breaks her silence on the viral The Girls Bathroom episode that exposed her fiance's infidelity and reveals Sophia Tuxford and Cinzia Baylis Zullo STILL haven't apologised
found
a story from The Daily Mail 💩 › The Daily Mail
While Lilly Sabri was sleeping, The Girls Bathroom podcast released a new episode about a man who had allegedly cheated on his well-known fiancee...
26 days ago
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
found
a story from The Economist ✅ › Business
Despite a late start, the American firm is bearing down on its Danish rival
31 days ago
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal
Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.
40 days ago
Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly's weight-loss drug Zepbound and its diabetes drug Mounjaro.
46 days ago
Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14%
The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight loss and diabetes market.
Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14%
The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight loss and diabetes market.
Eli Lilly shares surge on new obesity pill data. What it means for the stock from here
Jim Cramer said Eli Lilly's new trial data has turned the obesity market into a 'one-horse race.'